ImmunoCellin in vivo
The latest results in vivo confirm the efficacy of BioCellChallenge’s ImmunoCellin technology, which allows the antibody to pass through the cell membrane. No toxicity was observed at the administered doses.
In-vivo tests have shown that an anti-Ras antibody combined with ImmunoCellin technology slows tumor growth in all cases and leads to fullrecovery in one-third of cases.
The tests were conducted in 18 animal models, from January through July 2015. They showed that the intracellular delivery of a specific monoclonal antibody directed against the Ras oncoprotein, which is implicated in many cancers, significantly reduces the proliferation of tumor cells.In all cases, the animals’ lives were prolonged by up to 30%. Recovery was observed in 33% of cases. No toxicity-related mortality or inflammation was observed, or any abnormal change in the growth of the animal.